Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032414 | 0.86 | BTN3A1 (0.42) | BTN3A1L3MBTL1SRCMEN1KMT2A | |
| SCHEMBL3971071 | 0.85 | NPC1 (0.42) | MEN1KMT2AHTT | |
| SCHEMBL873273 | 0.76 | BTN3A1 (0.41) | LMNABTN3A1L3MBTL1 | |
| SCHEMBL3971351 | 0.76 | BTN3A1 (0.41) | LMNABTN3A1L3MBTL1 | |
| SCHEMBL3973571 | 0.73 | GAA (0.43) | LMNAPOLB | |
| SCHEMBL3973573 | 0.73 | GAA (0.43) | LMNAPOLB | |
| SCHEMBL1812000 | 0.73 | SMN1; SMN2 (0.41) | LMNAL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL7026588 | 0.71 | PGR (0.41) | LMNABTN3A1 | |
| SCHEMBL10566182 | 0.71 | L3MBTL1 (0.50) | L3MBTL1SRCMEN1KMT2APOLB | |
| SCHEMBL8894870 | 0.71 | L3MBTL1 (0.50) | L3MBTL1SRCMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009052050-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | TYMP, DTYMK, TYMS | LMNA 3715/4885BTN3A1 1100/4885L3MBTL1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.